Virology & Mycology
Open Access

Modulation of the status of influenza infection by Akt peptide inhibitor Akt-in

International Conference on Flu

June 08-10, 2015 Chicago, USA

Masayuki Noguchi, Noriyuki Hirata, Kohki Kimura, Mami Matsuda-Lennikov, Tatsuma Edamura, Jyoti Bala and Futoshi Suizu

ScientificTracksAbstracts-Workshop: Virol-mycol

Abstract :

The possibility of the pandemic spread of influenza viruses highlights the need for an effective cure for this life-threatening disease. Influenza A virus, belonging to a family of orthomyxoviruses is a negative-strand RNA virus which encodes 11 viral proteins. A number of intracellular signaling pathways in the host cells interact with influenza the viral proteins, which affect various stages of viral infection and replication. In this study, we investigated how inhibition of Akt kinase activity impacts on influenza virus infection by using �??Akt-in�?�, a peptide Akt inhibitor. In PR8 influenza-infected A549 cells, Akt interacted with the NS1 (Non structural protein1), and hence increased phosphorylation of Akt kinase activity and NS1. Treatment of cells with either �??TCL1-or TCL1b-based Akt-in�?� efficiently suppressed Akt kinase activity while decreasing the levels of phosphorylated NS1; this, in turn, inhibited viral replication in a dose- and time-dependent manner. The inhibitory effect on viral replication appears not due to inhibition of the production of inflammatory cytokines, including IL-6 and IL-8, in the host cells. Inhibition of Akt kinase activity in the host cells inhibited the efficiency of viral entry, which is associated with decreased levels of phosphorylated glycogen synthase kinase 3, a substrate of Akt. Further, Akt-in treatment of the host cells, which inhibited Akt kinase activity, modestly enhanced induction of autophagy. Taken together, inhibition of Akt kinase activity in host cells may have therapeutic advantages for influenza virus infection by inhibiting viral entry and replication.

Biography :

Masayuki Noguchi on October 2002, after spending 12 years in US at National Institute of Health in Bethesda (MD) and a faculty position at Harvard Medical School, took position as a full Professor of the Institute for Genetic Medicine, Division of Cancer Biology at Hokkaido University (Sapporo, Japan). His research interest is to clarify how the balance between cell death and survival regulates in vivo homeostasis. The molecules which he is currently focusing on serine threonine kinase Akt (also known as protein kinase B, PKB), a central regulatory component of the PI3K signaling pathways, which plays a pivotal role in the regulation of cell survival and proliferation to maintain in vivo homeostasis.